TRUITT et al. -- Appln. No.: 10/623,336

REMARKS

Reconsideration and allowance in view of the foregoing amendments and the following remarks are respectfully requested.

Claims 1-15, 24, and 31-33 remain pending in the present application.

Claims 1-15, 24, and 31-33 stand rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-5, 8-11, respectively, of U.S. Patent No. 6,622,724 to Truitt et al. ("the '724 patent"). As suggested by the Examiner, a Terminal Disclaimer executed by the undersigned applicant's representative in compliance with 37 C.F.R. § 1.321(c) is submitted herewith to disclaim the term of a patent resulting from the present application from extending beyond that of the '724 patent. Accordingly, applicants respectfully requests that the above obviousness-type double patent rejection be withdrawn.

The Commission is authorized to charge the Terminal Disclaimer fee required under 37 C.F.R. § 1.20(d) to deposit account no. 50-0558. Two copies of a Fee Transmittal form are submitted for this purpose.

All objections and rejections have been addressed. It is respectfully submitted that the present application is in condition for allowance and a Notice to the effect is earnestly solicited.

Respectfully submitted,

Michael W. Haas Reg. No.: 35,174

Reg. No.: 35,174 Tel. No.: (724) 387-5026

Fax No.: (724) 387-5021

RESPIRONICS, INC. 1010 Murry Ridge Lane Murrysville, PA 15668-8525

Note: The Commissioner is authorized to charge any fee required under 37 C.F.R. §§ 1.16 or 1.17 to deposit account no. 50-0558.